// App-Quantinova.ai

616 : Evolution of Outcome over Time for Relapsed Hodgkin Lymphoma after Autologous Stem Cell Transplant: Improved Survival for Early Relapse in Recent Years

Researchers

Presenter

  • Ali Bazarbachi

Principal Investigators

  • Herv Finel Sr

  • Irma Khvedelidze

  • Joanna Romejko-Jarosinska

  • Alina Daniela Tanase

  • Saad Akhtar

  • Tarek Ben Othman

  • Abdelghani Tbakhi

  • Boris Afanasyev

  • Javier Briones

  • Zafer Glbas

  • Jean Elcheikh

  • Rose-Marie Hamladji

  • Tugrul Elverdi

  • Didier Blaise

  • Carmen Martinez

  • Eleonora Alma

  • Kazimierz Halaburda

  • Aida Botelho de Sousa

  • Bertram Glass

  • Stephen Robinson

  • Silvia Montoto

  • Anna Sureda Balari

Medical Centers

  • Department of Cell Biology, Anatomy and Physiological Sciences, American University of Beirut, Beirut, Lebanon

  • Bone Marrow Transplantation Program, Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon

  • Leukemia Working Party of EBMT, Paris, France,

  • EBMT Lymphoma Working Party, Paris, France

  • Maria Sklodowska-Curie Institute-Oncology Center, Department of Lymphoid Malignancies,, warsaw, Poland

  • Bone Marrow Transplantation Unit, Fundeni Clinical Hospital, Bucharest, Romania

  • Oncology Center, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia

  • Hematology and transplant department, Centre National de Greffe de Moelle Osseuse de Tunis. Tunisia, Tunis, Tunisia

  • Department of Cell Therapy and Applied Genomics, King Hussein Cancer Center, Aurora, Canada

  • First State Pavlov Medical University of St. Petersburg Raisa Gorbacheva Memorial Research Institute for Paediatric Oncology, Hematology, and Transplantation, St Petersburg, Russian Federation

  • Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

  • Bone Marrow Transplantation Department, Anadolu Medical Center Hospital, Gebze, Turkey,

  • Bone Marrow Transplantation Program, Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon

  • Service Hematologie Greffe de Molle, Centre Pierre et Marie Curie, Alger, Algeria,

  • Department of Internal Medicine, Division of Hematology, Istanbul University, Cerrahpasa Medical Faculty, Istanbul, Turkey

  • Institut Paoli-Calmettes, Marseille, France

  • Hematopoietic Stem Cell Transplantation Unit, Hematology Department, Institute of Hematology and Oncology, IDIBAPS, Josep Carreras Research Institute, Hospital Clinic, Barcelona, Spain

  • University Policlinico Gemelli Foundation, IRCCS, Catholic University of the Sacred Heart, Roma, Italy

  • Institute of Hematology and Transfusion Medicine, Warsaw, Poland

  • Hospital dos Capuchos,, Lisboa, Portugal

  • Hospital dos Capuchos,, Lisboa, Portugal

  • Clinic for Hematology, Oncology, Tumorimmunology and Palliative Care, Helios Clinic Berlin-Buch, Berlin, Germany

  • University of Bristol, Bristol, United Kingdom

  • Division of Haemato-Oncology, St Bartholomews Hospital, Barts Health NHS Trust, London, United Kingdom

  • Institut Catala D'Oncologia. ICO Duran i Reinals, Hospitalet Del Llobregat, Spain

Locations

  • Lebanon

  • France

  • Poland

  • Romania

  • Saudi Arabia

  • Tunisia

  • Jordan

  • Russia

  • Spain

  • Turkey

  • Algeria

  • Portugal

  • Germany

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Hodgkin's Lymphoma

Biomarkers

  • N/A

Drug/Treatment

  • Adcetris

  • Pembrolizumab

  • Nivolumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved